<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: financial performance", fill: "#f4bbff"},
{source: "3: financial performance", target: "3: risks inherent", fill: "#f4bbff"},
{source: "3: risks inherent", target: "3: acquisition strategy", fill: "#f4bbff"},
{source: "3: acquisition strategy", target: "3: increased borrowing", fill: "#f4bbff"},
{source: "3: increased borrowing", target: "3: integration", fill: "#f4bbff"},
{source: "3: integration", target: "3: businesses", fill: "#f4bbff"},
{source: "3: businesses", target: "3: product lines", fill: "#f4bbff"},
{source: "3: financial performance", target: "4: expand through", fill: "#32127a"},
{source: "4: expand through", target: "4: acquisitions", fill: "#32127a"},
{source: "4: acquisitions", target: "4: pursue additional acquisitions", fill: "#32127a"},
{source: "4: expand through", target: "5: dependent", fill: "#f56991"},
{source: "5: dependent", target: "5: product lines into", fill: "#f56991"},
{source: "5: product lines into", target: "5: existing operations", fill: "#f56991"},
{source: "5: dependent", target: "8: addition while", fill: "#aaf0d1"},
{source: "8: addition while", target: "8: generally entitled", fill: "#aaf0d1"},
{source: "8: generally entitled", target: "8: indemnification from sellers", fill: "#aaf0d1"},
{source: "8: indemnification from sellers", target: "8: difficulties", fill: "#aaf0d1"},
{source: "8: difficulties", target: "8: acquisition", fill: "#aaf0d1"},
{source: "8: acquisition", target: "8: acquisitions may", fill: "#aaf0d1"},
{source: "8: acquisitions may", target: "8: involve exposure", fill: "#aaf0d1"},
{source: "8: involve exposure", target: "8: unknown liabilities", fill: "#aaf0d1"},
{source: "8: unknown liabilities", target: "8: indemnification provisions", fill: "#aaf0d1"},
{source: "8: addition while", target: "10: regulatory", fill: "#e6e8fa"},
{source: "10: regulatory", target: "10: requirements", fill: "#e6e8fa"},
{source: "10: requirements", target: "10: materially", fill: "#e6e8fa"},
{source: "10: materially", target: "10: implications", fill: "#e6e8fa"},
{source: "10: regulatory", target: "15: regulatory", fill: "#918151"},
{source: "15: regulatory", target: "15: requirements", fill: "#918151"},
{source: "15: requirements", target: "15: enforcement actions", fill: "#918151"},
{source: "15: enforcement actions", target: "15: partial suspension", fill: "#918151"},
{source: "15: partial suspension", target: "15: existing product approvals", fill: "#918151"},
{source: "15: existing product approvals", target: "15: clearances", fill: "#918151"},
{source: "15: clearances", target: "15: clear new applications", fill: "#918151"},
{source: "15: clear new applications", target: "15: increased quality control costs", fill: "#918151"},
{source: "15: increased quality control costs", target: "15: criminal prosecution", fill: "#918151"},
{source: "15: regulatory", target: "16: Quality System Regulations ", fill: "#5f9ea0"},
{source: "16: Quality System Regulations ", target: "16: regulations", fill: "#5f9ea0"},
{source: "16: regulations", target: "16: financial condition", fill: "#5f9ea0"},
{source: "16: financial condition", target: "16: operations", fill: "#5f9ea0"},
{source: "16: Quality System Regulations ", target: "17: manufacture products", fill: "#00ced1"},
{source: "17: manufacture products", target: "17: compliance with regulatory", fill: "#00ced1"},
{source: "17: compliance with regulatory", target: "17: cease manufacturing", fill: "#00ced1"},
{source: "17: cease manufacturing", target: "17: product recall", fill: "#00ced1"},
{source: "17: manufacture products", target: "24: highly competitive market", fill: "#555d50"},
{source: "24: highly competitive market", target: "24: products may", fill: "#555d50"},
{source: "24: products may", target: "24: adverse pricing", fill: "#555d50"},
{source: "24: highly competitive market", target: "26: competitors", fill: "#c19a6b"},
{source: "26: competitors", target: "26: organizations", fill: "#c19a6b"},
{source: "26: competitors", target: "39: towards managed care cuts", fill: "#228b22"},
{source: "39: towards managed care cuts", target: "39: Medicare ", fill: "#228b22"},
{source: "39: Medicare ", target: "39: consolidation", fill: "#228b22"},
{source: "39: consolidation", target: "39: distribution companies", fill: "#228b22"},
{source: "39: distribution companies", target: "39: collective", fill: "#228b22"},
{source: "39: collective", target: "39: purchasing arrangements by", fill: "#228b22"},
{source: "39: purchasing arrangements by", target: "39: GPOs and IHNs", fill: "#228b22"},
{source: "39: towards managed care cuts", target: "42: characterized by rapidly", fill: "#cd9575"},
{source: "42: characterized by rapidly", target: "42: technology", fill: "#cd9575"},
{source: "42: characterized by rapidly", target: "46: new products may fail", fill: "#967bb6"},
{source: "46: new products may fail", target: "46: market acceptance", fill: "#967bb6"},
{source: "46: new products may fail", target: "52: agreement contains covenants which may limit", fill: "#86608e"},
{source: "52: agreement contains covenants which may limit", target: "52: flexibility", fill: "#86608e"},
{source: "52: flexibility", target: "52: prevent us from", fill: "#86608e"},
{source: "52: agreement contains covenants which may limit", target: "53: agreement contains", fill: "#e6e200"},
{source: "53: agreement contains", target: "53: facilities", fill: "#e6e200"},
{source: "53: facilities", target: "53: respects significantly limit", fill: "#e6e200"},
{source: "53: respects significantly limit", target: "53: prohibit among", fill: "#e6e200"},
{source: "53: prohibit among", target: "53: incur indebtedness", fill: "#e6e200"},
{source: "53: incur indebtedness", target: "53: investments", fill: "#e6e200"},
{source: "53: investments", target: "53: transactions with affiliates", fill: "#e6e200"},
{source: "53: transactions with affiliates", target: "53: pay dividends", fill: "#e6e200"},
{source: "53: pay dividends", target: "53: distributions on", fill: "#e6e200"},
{source: "53: distributions on", target: "53: capital stock", fill: "#e6e200"},
{source: "53: capital stock", target: "53: sell assets", fill: "#e6e200"},
{source: "53: sell assets", target: "53: pursue acquisitions", fill: "#e6e200"},
{source: "53: agreement contains", target: "57: repay such borrowings", fill: "#ffa500"},
{source: "57: repay such borrowings", target: "57: agreement lenders could proceed", fill: "#ffa500"},
{source: "57: agreement lenders could proceed", target: "57: against collateral securing", fill: "#ffa500"},
{source: "57: against collateral securing", target: "57: agreement which consists", fill: "#ffa500"},
{source: "57: agreement which consists", target: "57: substantially", fill: "#ffa500"},
{source: "57: substantially", target: "57: assets except", fill: "#ffa500"},
{source: "57: assets except", target: "57: accounts", fill: "#ffa500"},
{source: "57: accounts", target: "57: rights which", fill: "#ffa500"},
{source: "57: rights which", target: "57: connection with", fill: "#ffa500"},
{source: "57: connection with", target: "57: receivable sales agreement", fill: "#ffa500"},
{source: "57: repay such borrowings", target: "95: insurance coverage", fill: "#f400a1"},
{source: "95: insurance coverage", target: "95: product liability", fill: "#f400a1"},
{source: "95: insurance coverage", target: "START_HERE", fill: "#f400a1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_acquisition">Language acquisition</a></td>
      <td>Language acquisition is the process by which humans acquire the capacity to perceive and comprehend language (in other words, gain the ability to be aware of language and to understand it), as well as to produce and use words and sentences to communicate.\nLanguage acquisition involves structures, rules and representation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_British_citizens">Visa requirements for British citizens</a></td>
      <td>Visa requirements for British citizens are administrative entry restrictions by the authorities of other states placed on citizens of the United Kingdom. As of 30 April 2022, British citizens had visa-free or visa on arrival access to 187 countries and territories, ranking their passport 5th in terms of travel freedom (tied with France, Ireland and Portugal) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cost_accounting">Cost accounting</a></td>
      <td>Cost accounting is defined as "a systematic set of procedures for recording and reporting measurements of the cost of manufacturing goods and performing services in the aggregate and in detail. It includes methods for recognizing, classifying, allocating, aggregating and reporting such costs and comparing them with standard costs." (IMA)  Often considered a subset of managerial accounting, its end goal is to advise the management on how to optimize business practices and processes based on cost efficiency and capability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_recall">Product recall</a></td>
      <td>A product recall is a request from a manufacturer to return a product after the discovery of safety issues or product defects that might endanger the consumer or put the maker/seller at risk of legal action.\nThe recall is an effort to limit ruination of the corporate image and limit liability for corporate negligence, which can cause significant legal costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Affordable_Care_Act">Affordable Care Act</a></td>
      <td>The Affordable Care Act (ACA), formally known as the Patient Protection and Affordable Care Act, and colloquially known as Obamacare, is a landmark U.S. federal statute enacted by the 111th United States Congress and signed into law by President Barack Obama on March 23, 2010. Together with the Health Care and Education Reconciliation Act of 2010 amendment, it represents the U.S. healthcare system's most significant regulatory overhaul and expansion of coverage since the enactment of Medicare and Medicaid in 1965.The ACA's major provisions came into force in 2014.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_insurance_in_the_United_States">Health insurance in the United States</a></td>
      <td>Health insurance in the United States is any program that helps pay for medical expenses, whether through privately purchased insurance, social insurance, or a social welfare program funded by the government. Synonyms for this usage include "health coverage", "health care coverage", and "health benefits".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hatchback">Hatchback</a></td>
      <td>A hatchback is a car body configuration with a rear door that swings upward to provide access to a cargo area. Hatchbacks may feature fold-down second row seating, where the interior can be reconfigured to prioritize passenger or cargo volume.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sherlock_Automated_Design_Analysis">Sherlock Automated Design Analysis</a></td>
      <td>Sherlock Automated Design Analysis is a software tool developed by DfR Solutions for analyzing, grading, and certifying the expected reliability of products at the circuit card assembly level. Based on the science of Physics of Failure, Sherlock predicts failure mechanism-specific failure rates over time using a combination of finite element method and material properties to capture stress values and first order analytical equations to evaluate damage evolution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pocket-sized_computer">Pocket-sized computer</a></td>
      <td>Pocket-sized computer describes the post-programmable calculator / pre-smartphone pocket-sized portable-office hardware devices that included the earlier DOS-based palmtops and subsequent Windows-CE handhelds, as well as a few other terms, primarily covering the 1980s through 2007.\nSometimes called Pocket-sized computing devices, they were a series of internally different  devices, and included Handheld ("Pocket-sized handheld computing device"), and the earlier-introduced Palmtop\n("Pocket-sized palmtop computing device") and "pocket-sized palmtop computer." The New York Times used the term "palmtop/handheld."The media called "the first computer that fits in your palm and weighs less than a pound" and its early day competitors a palmtop.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Modular_building">Modular building</a></td>
      <td>A modular building is a prefabricated building that consists of repeated sections called modules. Modularity involves constructing sections away from the building site, then delivering them to the intended site.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenuptial_agreement">Prenuptial agreement</a></td>
      <td>A prenuptial agreement, antenuptial agreement, or premarital agreement (commonly referred to as a prenup), is a written contract entered into by a couple prior to marriage or a civil union that enables them to select and control many of the legal rights they acquire upon marrying, and what happens when their marriage eventually ends by death or divorce. Couples enter into a written prenuptial agreement to supersede many of the default marital laws that would otherwise apply in the event of divorce, such as the laws that govern the division of property, retirement benefits, savings, and the right to seek alimony (spousal support) with agreed-upon terms that provide certainty and clarify their marital rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Debt">Debt</a></td>
      <td>Death is the irreversible cessation of all biological functions that sustain an organism. Brain death is sometimes used as a legal definition of death.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Loan">Loan</a></td>
      <td>A man is an adult male human. Prior to adulthood, a male human is referred to as a boy (a male child or adolescent).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Accounts_receivable">Accounts receivable</a></td>
      <td>Accounts receivable, abbreviated as AR or A/R, are legally enforceable claims for payment held by a business for goods supplied or services rendered that customers have ordered but not paid for. These are generally in the form of invoices raised by a business and delivered to the customer for payment within an agreed time frame.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Insurance">Insurance</a></td>
      <td>Securitization is the financial practice of pooling various types of contractual debt such as residential mortgages, commercial mortgages, auto loans or credit card debt obligations (or other non-debt assets which generate receivables) and selling their related cash flows to third party investors as securities, which may be described as bonds, pass-through securities, or collateralized debt obligations (CDOs). Investors are repaid from the principal and interest cash flows collected from the underlying debt and redistributed through the capital structure of the new financing.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CONMED CORP      Item 1A  Risk Factors                         An <font color="blue">investment</font> in our securities, including our common     stock, involves a high degree of risk</td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font><font color="blue">should carefully</font> consider     the <font color="blue">specific factors set forth</font> below as well as the other information     included or <font color="blue">incorporated by reference</font> in this Form 10-K See “Forward     Looking Statements”</td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial performance</font> is subject to the <font color="blue">risks inherent</font> in our     <font color="blue"><font color="blue">acquisition</font> strategy</font>, including the effects of <font color="blue">increased borrowing</font> and     <font color="blue">integration</font> of newly acquired <font color="blue">businesses</font> or <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>A key element of our business strategy has been to <font color="blue">expand through</font>     <font color="blue"><font color="blue">acquisition</font>s</font> and we may seek to pursue additional <font color="blue"><font color="blue">acquisition</font>s</font> in the     future</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent</font> in part upon our ability to integrate     acquired companies or <font color="blue">product lines</font> into our <font color="blue">existing <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>We may not     have <font color="blue">sufficient management</font> and other resources to accomplish the <font color="blue">integration</font>     of our past and future <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue">implementing</font> our <font color="blue">acquisition</font>     <font color="blue">strategy may</font> strain our relationship with customers, suppliers,     distributors, <font color="blue">manufacturing</font> personnel or others</td>
    </tr>
    <tr>
      <td>There can be no assurance     that we will be able to identify and make <font color="blue"><font color="blue">acquisition</font>s</font> on acceptable terms     or that we will be able to obtain financing for such <font color="blue"><font color="blue">acquisition</font>s</font> on     acceptable terms</td>
    </tr>
    <tr>
      <td>In addition, while we are <font color="blue"><font color="blue">generally</font> entitled</font> to customary     <font color="blue">indemnification from sellers</font> of <font color="blue">businesses</font> for any <font color="blue"><font color="blue">difficult</font>ies</font> that may     have arisen prior to our <font color="blue">acquisition</font> of each business, <font color="blue"><font color="blue">acquisition</font>s</font> may     <font color="blue">involve exposure</font> to <font color="blue">unknown liabilities</font> and the amount and time for claiming     under these <font color="blue">indemnification provisions</font> is often limited</td>
    </tr>
    <tr>
      <td>As a result, our     <font color="blue">financial performance</font> is now and <font color="blue">will continue</font> to be subject to various     <font color="blue">risks <font color="blue">associated with</font></font> the <font color="blue">acquisition</font> of <font color="blue">businesses</font>, including the financial     effects <font color="blue">associated with</font> any <font color="blue">increased borrowing</font> required to fund such     <font color="blue"><font color="blue">acquisition</font>s</font> or with the <font color="blue">integration</font> of such <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> may result in recalls,     fines or <font color="blue">materially</font> adverse <font color="blue">implications</font></td>
    </tr>
    <tr>
      <td>All of our products are classified as <font color="blue">medical devices</font> subject to regulation     by  the  FDA  As a <font color="blue"><font color="blue">manufacture</font>r</font> of <font color="blue">medical devices</font>, our <font color="blue">manufacturing</font>     processes and <font color="blue">facilities</font> are subject to on-site inspection and continuing     review  by the FDA for compliance with <font color="blue">the Quality System Regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>and sales of our products outside <font color="blue">the United States </font>are also     subject to foreign <font color="blue">regulatory</font> <font color="blue">requirements</font> which vary from country to                                        -20-       _________________________________________________________________         country</td>
    </tr>
    <tr>
      <td>Moreover, we are <font color="blue">generally</font> required to obtain <font color="blue">regulatory</font> clearance     or <font color="blue">approval prior</font> to marketing a new product</td>
    </tr>
    <tr>
      <td>The time required to obtain     approvals from <font color="blue">foreign countries</font> may be longer or <font color="blue">shorter than</font> that required     for FDA approval, and <font color="blue">requirements</font> for <font color="blue">foreign approvals may differ from</font> FDA     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable domestic and/or foreign     <font color="blue">regulatory</font> <font color="blue">requirements</font> may result in:         • fines or other <font color="blue">enforcement actions</font>;         • recall or seizure of products;         • total or <font color="blue">partial suspension</font> of production;         • withdrawal of <font color="blue">existing product approvals</font> or <font color="blue">clearances</font>;         • refusal to approve or <font color="blue">clear new applications</font> or notices;         • <font color="blue">increased quality control costs</font>; or         • <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> <font color="blue">Quality System Regulations </font>and applicable foreign     <font color="blue">regulations</font> could result in a material adverse effect on our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue"><font color="blue">manufacture</font> products</font> in compliance with <font color="blue">regulatory</font>     standards, we may decide to cease <font color="blue">manufacturing</font> of those products and may be     subject to <font color="blue">product recall</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">the Quality System Regulations</font>, many of our products are also     subject to industry-defined standards</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">comply with</font>     these <font color="blue">regulations</font> and <font color="blue">standards due</font> to <font color="blue">deficiencies</font> in component parts or     our <font color="blue">manufacturing</font> processes</td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue">comply with</font> the Quality     System Regulations or industry-defined standards, we may not be able to fill     customer orders and we may decide to cease production of non-compliant     products</td>
    </tr>
    <tr>
      <td>Our products are subject to <font color="blue">product recall</font> and we have made <font color="blue">product recall</font>s     in the past</td>
    </tr>
    <tr>
      <td>Although no recall has had a material adverse effect on our     business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font>, we <font color="blue">cannot assure</font> you     that <font color="blue">regulatory</font> issues will not have a material adverse effect in the future     or that <font color="blue">product recall</font>s will not harm our reputation and our customer     <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">highly <font color="blue">competitive</font></font> market</font> for our <font color="blue">products may</font> create <font color="blue">adverse pricing</font>     pressures</td>
    </tr>
    <tr>
      <td>The market for our products is <font color="blue">highly <font color="blue">competitive</font></font> and our customers have     <font color="blue">numerous <font color="blue">alternative</font>s</font> of supply</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> offer a range of     products in areas other than those in which we compete, which may make such     <font color="blue">competitors</font> more attractive to surgeons, hospitals, group purchasing     <font color="blue">organizations</font> and others</td>
    </tr>
    <tr>
      <td>In addition, several of our <font color="blue">competitors</font> are large,     technically-competent firms with substantial assets</td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font>pricing     pressures or the <font color="blue">introduction</font> of <font color="blue"><font color="blue">new products</font> by</font> our <font color="blue">competitors</font> could have     an adverse effect on our revenues</td>
    </tr>
    <tr>
      <td>See “Competition” for a further     discussion of these <font color="blue"><font color="blue">competitive</font> forces</font></td>
    </tr>
    <tr>
      <td>-21-       _________________________________________________________________         Factors <font color="blue">which may influence</font> our customers’ choice of <font color="blue">competitor products</font>     include:       •     changes in <font color="blue">surgeon preferences</font>;         •     increases or <font color="blue">decreases</font> in health care spending related to <font color="blue">medical devices</font>;         •     our <font color="blue">inability</font> to <font color="blue">supply products</font> to them, as a result of <font color="blue">product recall</font>,     <font color="blue">market withdrawal</font> or back-order;       •     the <font color="blue">introduction</font> by <font color="blue">competitors</font> of <font color="blue">new products</font> or new features to existing     products;       •     the <font color="blue">introduction</font> by <font color="blue">competitors</font> of <font color="blue"><font color="blue">alternative</font> surgical <font color="blue">technology</font></font>; and       •     advances in surgical procedures, discoveries or <font color="blue"><font color="blue">development</font>s</font> in the health     <font color="blue">care industry</font></td>
    </tr>
    <tr>
      <td>We use a variety of <font color="blue">raw materials</font> in our <font color="blue">businesses</font>, and <font color="blue">significant</font>     shortages or <font color="blue"><font color="blue">price increases</font> could increase</font> our operating costs and     <font color="blue"><font color="blue">adversely</font> impact</font> the <font color="blue"><font color="blue">competitive</font> positions</font> of our products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">reliance on certain suppliers</font> and commodity markets to <font color="blue">secure raw</font>     materials used in our <font color="blue">products exposes us</font> to <font color="blue">volatility</font> in the prices and     <font color="blue">availability</font>  of  raw  materials</td>
    </tr>
    <tr>
      <td>In some instances, we <font color="blue">participate</font> in     commodity  markets  that may be subject to <font color="blue">allocations by suppliers</font></td>
    </tr>
    <tr>
      <td>A     <font color="blue">disruption</font> in <font color="blue">deliveries from</font> our suppliers, <font color="blue">price increases</font>, or decreased     <font color="blue">availability</font> of <font color="blue">raw materials</font> or commodities, could have an adverse effect     on  our  ability  to meet our <font color="blue"><font color="blue">commitment</font>s</font> to customers or increase our     operating costs</td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">supply management practices</font> are based     on  an <font color="blue">appropriate balancing</font> of the <font color="blue">foreseeable risks</font> and the costs of     <font color="blue"><font color="blue">alternative</font> practices</font></td>
    </tr>
    <tr>
      <td>Nonetheless, <font color="blue">price increases</font> or the un<font color="blue">availability</font> of     some <font color="blue">raw materials</font> may have an adverse effect on our results of <font color="blue">operations</font>     or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Cost <font color="blue">reduction efforts</font> in the health <font color="blue">care industry</font> could put pressures on     our prices and margins</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, the health <font color="blue">care industry</font> has undergone <font color="blue">significant</font> change     <font color="blue">driven by various efforts</font> to <font color="blue">reduce costs</font></td>
    </tr>
    <tr>
      <td>Such efforts include national     health  care  reform,  trends  towards managed care, cuts in Medicare,     <font color="blue">consolidation</font>  of  health  care  <font color="blue">distribution companies</font> and <font color="blue">collective</font>     <font color="blue">purchasing arrangements by</font> <font color="blue">GPOs and IHNs</font></td>
    </tr>
    <tr>
      <td>Demand and prices for our products     may be <font color="blue">adversely</font> affected by such trends</td>
    </tr>
    <tr>
      <td>We may not be able to keep <font color="blue">pace with technological</font> change or to <font color="blue">successfully</font>     develop <font color="blue">new products</font> with wide <font color="blue">market acceptance</font>, <font color="blue">which could</font> cause us to     lose business to <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The market for our products is <font color="blue">characterized by rapidly</font> changing <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our future <font color="blue">financial performance</font> will depend in part on our ability to     develop and <font color="blue"><font color="blue">manufacture</font> <font color="blue">new products</font> on</font> a cost-effective basis, to introduce     them to the <font color="blue">market on</font> a <font color="blue">timely basis</font>, and to have <font color="blue">them accepted by surgeons</font></td>
    </tr>
    <tr>
      <td>We may not be able to keep pace with <font color="blue">technology</font> or to develop <font color="blue">viable new</font>     products</td>
    </tr>
    <tr>
      <td>Factors which may result in delays of new product <font color="blue">introduction</font>s or     <font color="blue">cancellation</font> of our plans to <font color="blue">manufacture</font> and <font color="blue">market <font color="blue">new products</font></font> include:         • <font color="blue">capital constraints</font>;         • research and <font color="blue"><font color="blue">development</font> delays</font>;         • delays in securing <font color="blue">regulatory</font> approvals; or                                        -22-       _________________________________________________________________       •     changes in the <font color="blue"><font color="blue">competitive</font> landscape</font>, including the emergence of <font color="blue">alternative</font>     products or <font color="blue">solutions which reduce</font> or eliminate the markets for pending     products</td>
    </tr>
    <tr>
      <td>Our new <font color="blue">products may</font> fail to achieve expected levels of     <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>New product <font color="blue">introduction</font>s may fail to achieve <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>The degree     of <font color="blue">market acceptance</font> for any of our products will depend upon a number of     factors, including:       •     our ability to develop and <font color="blue">introduce <font color="blue">new products</font></font> and <font color="blue">product enhancements</font>     in the time frames we currently estimate;       •     our ability to <font color="blue">successfully</font> implement <font color="blue">new technologies</font>;       •     the market’s readiness to <font color="blue">accept <font color="blue">new products</font></font>;       •     having <font color="blue">adequate financial</font> and <font color="blue">technological resources</font> for <font color="blue">future product</font>     <font color="blue">development</font> and promotion;       •     the efficacy of our products; and       •      the prices of our <font color="blue">products compared</font> to the prices of our <font color="blue">competitors</font>’     products</td>
    </tr>
    <tr>
      <td>If our <font color="blue">new products</font> do not achieve <font color="blue">market acceptance</font>, we may be unable to     recover our <font color="blue">investment</font>s and may lose business to <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In addition, some of the <font color="blue">companies with which</font> we now compete or may compete     in the future have or may have more extensive research, marketing and     <font color="blue">manufacturing</font> capabilities and <font color="blue">significant</font>ly greater technical and personnel     <font color="blue">resources than</font> we do, and may be <font color="blue">better positioned</font> to continue to improve     their <font color="blue">technology</font> in order to compete in an <font color="blue">evolving industry</font></td>
    </tr>
    <tr>
      <td>See     “Competition” for a further discussion of these <font color="blue"><font color="blue">competitive</font> forces</font></td>
    </tr>
    <tr>
      <td>Our senior credit <font color="blue"><font color="blue"><font color="blue">agreement</font> contains</font> covenants which may limit</font> our     <font color="blue">flexibility</font> or <font color="blue">prevent us from</font> taking actions</td>
    </tr>
    <tr>
      <td>Our senior credit <font color="blue"><font color="blue">agreement</font> contains</font>, and future credit <font color="blue">facilities</font> are     expected to contain, certain restrictive covenants which will affect, and in     many respects <font color="blue">significant</font>ly limit or prohibit, among other things, our     ability to:         • <font color="blue">incur <font color="blue">indebtedness</font></font>;         • make <font color="blue">investment</font>s;         • engage in <font color="blue">transactions with affiliates</font>;         • <font color="blue">pay dividends</font> or make other <font color="blue">distributions on</font>, or redeem or repurchase,     <font color="blue">capital stock</font>;         •     <font color="blue">sell assets</font>; and         • pursue <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>These covenants, unless waived, may <font color="blue">prevent us from</font> pursuing <font color="blue"><font color="blue">acquisition</font>s</font>,     <font color="blue">significant</font>ly limit our operating and financial <font color="blue">flexibility</font> and limit our     ability to respond to changes in our business or <font color="blue"><font color="blue">competitive</font> activities</font></td>
    </tr>
    <tr>
      <td>Our     ability to <font color="blue">comply with</font> such provisions may be <font color="blue">affected by events beyond</font> our     control</td>
    </tr>
    <tr>
      <td>In the event of any <font color="blue">default under</font> our credit <font color="blue">agreement</font>, the credit     <font color="blue">agreement</font> lenders may elect to declare all <font color="blue">amounts borrowed under</font> our credit     <font color="blue">agreement</font>, together with accrued interest, to be due and payable</td>
    </tr>
    <tr>
      <td>If we were     unable to <font color="blue">repay such <font color="blue">borrowings</font></font>, the credit <font color="blue">agreement</font> lenders could proceed                                        -23-       _________________________________________________________________         <font color="blue">against collateral securing</font> the credit <font color="blue">agreement</font>, which consists of     <font color="blue">substantially</font> all of our property and assets, except for our <font color="blue">accounts</font>     receivable and related <font color="blue">rights which</font> are sold in <font color="blue">connection with</font> the <font color="blue">accounts</font>     receivable sales <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>See “Management’s Discussion and Analysis of     Financial Condition and Results of Operations—Liquidity and Capital     Resources” for a discussion of the <font color="blue">accounts</font> receivable sales <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Our     credit <font color="blue">agreement</font> also contains a material adverse effect <font color="blue">clause which may</font>     limit our ability to <font color="blue">access additional funding under</font> our credit <font color="blue">agreement</font>     should a material adverse change in our business occur</td>
    </tr>
    <tr>
      <td>Our substantial leverage and <font color="blue">debt service</font> <font color="blue">requirements</font> may require us to     adopt <font color="blue">alternative</font> business strategies</td>
    </tr>
    <tr>
      <td>We have <font color="blue">indebtedness</font> that is substantial in relation to our <font color="blue">shareholders</font>’     equity, as well as interest and <font color="blue">debt service</font> <font color="blue">requirements</font> that are     <font color="blue">significant</font> compared to our cash flow from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31,     2005, we had dlra306dtta9 million of debt outstanding, representing 40prca of total     <font color="blue">capitalization</font> and which does not include the dlra40 million of <font color="blue">accounts</font>     <font color="blue">receivable sold under</font> the <font color="blue">accounts</font> receivable sales <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>See     “Management’s Discussion and Analysis of Financial Condition and Results of     Operations—Liquidity and Capital Resources”</td>
    </tr>
    <tr>
      <td>The degree to which we are <font color="blue">leveraged could</font> have <font color="blue">important consequences</font> to     investors, including but not limited to the following:       •     a substantial portion of our cash flow from <font color="blue">operations</font> must be dedicated to     <font color="blue">debt service</font> and will not be available for <font color="blue">operations</font>, capital expenditures,     <font color="blue"><font color="blue">acquisition</font>s</font>, dividends and other purposes;       •     our ability to obtain <font color="blue">additional financing</font> in the future for working     capital, capital expenditures, <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">general corporate purposes</font>     may be limited or impaired, or may be <font color="blue">at higher interest rates</font>;       •     we may be at a <font color="blue"><font color="blue">competitive</font> disadvantage</font> when compared to <font color="blue">competitors</font> that     are <font color="blue">less leveraged</font>;       •     we may be hindered in our ability to <font color="blue">adjust rapidly</font> to <font color="blue">market conditions</font>;       •     our degree of <font color="blue">leverage could</font> make us more vulnerable in the event of a     downturn in <font color="blue">general economic conditions</font> or other <font color="blue">adverse circumstances</font>     applicable to us; and           •     our <font color="blue">interest expense could increase</font> if interest rates in <font color="blue">general increase</font>     because a portion of our <font color="blue">borrowings</font>, including our <font color="blue">borrowings</font> under our     credit <font color="blue">agreement</font>, are and <font color="blue">will continue</font> to be <font color="blue">at variable rates</font> of interest</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">generate sufficient cash</font> to service our <font color="blue">indebtedness</font>,     <font color="blue">which could</font> require us to reduce our expenditures, <font color="blue">sell assets</font>, restructure     our <font color="blue">indebtedness</font> or <font color="blue">seek additional equity capital</font></td>
    </tr>
    <tr>
      <td>Our ability to satisfy our <font color="blue"><font color="blue">obligations</font> will depend upon</font> our future operating     performance, which will be <font color="blue">affected by prevailing economic conditions</font> and     financial, business and other factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient cash flow available</font> to <font color="blue">enable us</font> to meet our     <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If we are unable to service our <font color="blue">indebtedness</font>, we will be forced     to adopt an <font color="blue">alternative</font> strategy that may include <font color="blue">actions such as foregoing</font>     <font color="blue"><font color="blue">acquisition</font>s</font>, reducing or delaying capital expenditures, selling assets,     <font color="blue">restructuring</font> or <font color="blue">refinancing</font> our <font color="blue">indebtedness</font> or <font color="blue">seeking additional equity</font>     capital</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of these <font color="blue">strategies could</font> be                                        -24-       _________________________________________________________________         <font color="blue">implemented on terms</font> acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>See “Management’s     Discussion and Analysis of Financial Condition and Results of Operations –     Liquidity and Capital Resources” for a discussion of our <font color="blue">indebtedness</font> and     its <font color="blue">implications</font></td>
    </tr>
    <tr>
      <td>We may be unable to continue to sell our <font color="blue">accounts</font> receivable, <font color="blue">which could</font>     require us to seek <font color="blue">alternative</font> sources of financing</td>
    </tr>
    <tr>
      <td>Under our <font color="blue">accounts</font> receivable sales <font color="blue">agreement</font>, there are <font color="blue">certain statistical</font>     <font color="blue">ratios which must</font> be maintained relating to the pool of <font color="blue">receivables</font> in order     for us to <font color="blue">continue selling</font> to the purchaser</td>
    </tr>
    <tr>
      <td>These ratios relate to sales     dilution and losses on <font color="blue">accounts</font> receivable</td>
    </tr>
    <tr>
      <td>If new <font color="blue">accounts</font> receivable     arising in the <font color="blue">normal course</font> of business do not qualify for sale or the     purchaser otherwise ceases to purchase our <font color="blue">receivables</font>, we may require     access to <font color="blue">alternate sources</font> of working capital, which may be more expensive     or <font color="blue">difficult</font> to obtain</td>
    </tr>
    <tr>
      <td>Our <font color="blue">accounts</font> receivable sales <font color="blue">agreement</font>, as amended,     also requires us to obtain a <font color="blue">commitment</font> (the “purchaser <font color="blue">commitment</font>”), on an     <font color="blue">annual basis from</font> the purchaser to fund the purchase of our <font color="blue">accounts</font>     receivable</td>
    </tr>
    <tr>
      <td>The purchaser <font color="blue">commitment</font> was <font color="blue">amended effective</font> October 21, 2005     whereby it was extended for an <font color="blue">additional year</font></td>
    </tr>
    <tr>
      <td>In the event we are unable     to renew our purchaser <font color="blue">commitment</font> in the future, we would need to access     <font color="blue">alternate sources</font> of working <font color="blue">capital which may</font> be more expensive or     <font color="blue">difficult</font> to obtain</td>
    </tr>
    <tr>
      <td>If we infringe third parties’ patents, or if we lose our patents or they are     held to be invalid, we <font color="blue">could become</font> subject to <font color="blue">liability</font> and our <font color="blue">competitive</font>     <font color="blue">position could</font> be harmed</td>
    </tr>
    <tr>
      <td>Much of the <font color="blue">technology</font> used in the markets in which we compete is <font color="blue">covered by</font>     patents</td>
    </tr>
    <tr>
      <td>We have numerous US patents and <font color="blue">corresponding foreign patents on</font>     products expiring at various dates from 2006 through 2023 and have     <font color="blue">additional patent applications pending</font></td>
    </tr>
    <tr>
      <td>See “Research and Development” for a     further description of our patents</td>
    </tr>
    <tr>
      <td>The loss of our <font color="blue">patents could reduce</font> the     value of the related products and any related <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may also be able to <font color="blue">design around</font> our patents and to compete     <font color="blue">effectively with</font> our products</td>
    </tr>
    <tr>
      <td>In addition, the cost of enforcing our     <font color="blue">patents against third parties</font> and defending our <font color="blue">products against patent</font>     <font color="blue"><font color="blue">infringement</font> actions by others could</font> be substantial</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that:       •     <font color="blue">pending patent applications will</font> result in <font color="blue">issued patents</font>,         •     <font color="blue">patents issued</font> to or <font color="blue">licensed by us will</font> not be challenged by <font color="blue">competitors</font>,         •     our <font color="blue">patents will</font> be found to be valid or <font color="blue">sufficiently broad</font> to protect our     <font color="blue">technology</font> or <font color="blue">provide us with</font> a <font color="blue">competitive</font> advantage, or       •     we will be successful in <font color="blue">defending against pending</font> or <font color="blue">future patent</font>     <font color="blue">infringement</font> claims asserted against our products</td>
    </tr>
    <tr>
      <td>Ordering patterns of our <font color="blue">customers may</font> change resulting in <font color="blue">reductions</font> in     sales</td>
    </tr>
    <tr>
      <td>Our hospital and <font color="blue">surgery center customers purchase</font> our products in     <font color="blue">quantities sufficient</font> to meet their anticipated demand</td>
    </tr>
    <tr>
      <td>Likewise, our health     <font color="blue">care <font color="blue">distributor customers</font> purchase</font> our products for <font color="blue">ultimate resale</font> to     <font color="blue">health care providers</font> in <font color="blue">quantities sufficient</font> to meet the anticipated     <font color="blue">requirements</font> of the distributors’ customers</td>
    </tr>
    <tr>
      <td>Should <font color="blue">inventories</font> of our     products owned by our hospital, surgery center and <font color="blue">distributor customers</font>     grow to <font color="blue">levels higher than</font> their <font color="blue">requirements</font>, our <font color="blue">customers may</font> reduce the     ordering of products                                        -25-       _________________________________________________________________         from us</td>
    </tr>
    <tr>
      <td>This could result in <font color="blue">reduced sales during</font> a <font color="blue">financial accounting</font>     period</td>
    </tr>
    <tr>
      <td>Our <font color="blue">significant</font> international <font color="blue">operations</font> subject us to <font color="blue">risks <font color="blue">associated with</font></font>     operating in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our revenues are <font color="blue">derived from foreign sales</font></td>
    </tr>
    <tr>
      <td>As a     result, our international presence exposes us to certain inherent risks,     including:         •     <font color="blue">devaluations</font> and <font color="blue">fluctuations</font> in currency exchange rates;         •     imposition of <font color="blue">limitations</font> on <font color="blue">conversions</font> of foreign currencies into dollars     or remittance of dividends and other <font color="blue">payments by international subsidiaries</font>;       •     imposition or increase of withholding and other <font color="blue">taxes on remittances</font> and     other <font color="blue">payments by international subsidiaries</font>;       •     <font color="blue">trade barriers</font>;       •     <font color="blue">political risks</font>, including <font color="blue">political instability</font>;       •     <font color="blue">reliance on third parties</font> to distribute our products;       •     <font color="blue">hyperinflation</font> in certain <font color="blue">foreign countries</font>; and       •     imposition or increase of <font color="blue">investment</font> and other <font color="blue">restrictions by foreign</font>     <font color="blue">governments</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">such risks will</font> not have a material adverse effect     on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We can be sued for producing defective products and our <font color="blue">insurance coverage</font>     may be insufficient to cover the nature and amount of any product <font color="blue">liability</font>     claims</td>
    </tr>
    <tr>
      <td>The nature of our products as <font color="blue">medical devices</font> and today’s litigious     <font color="blue">environment should</font> be regarded as potential risks <font color="blue">which could</font> <font color="blue">significant</font>ly     and <font color="blue">adversely</font> affect our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The     insurance we maintain to <font color="blue">protect against</font> claims <font color="blue">associated with</font> the use of     our products have <font color="blue">deductibles</font> and may not <font color="blue">adequately cover</font> the amount or     nature of any claim asserted <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also exposed</font> to the risk     that our <font color="blue">insurers may become insolvent</font> or that <font color="blue">premiums may increase</font>     <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>See “Legal Proceedings” for a further discussion of the risk     of product <font color="blue">liability</font> actions and our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Damage to our physical properties as a result of windstorm, earthquake, fire     or other natural or man-made disaster may cause a <font color="blue">financial loss</font> and a loss     of customers</td>
    </tr>
    <tr>
      <td>Although we maintain <font color="blue">insurance coverage</font> for <font color="blue">physical damage</font> to our property     and the <font color="blue">resultant losses</font> that could occur during a business <font color="blue">interruption</font>, we     are required to pay <font color="blue">deductibles</font> and our <font color="blue">insurance coverage</font> is limited to     <font color="blue">certain caps</font></td>
    </tr>
    <tr>
      <td>For example, our deductible for <font color="blue">windstorm damage</font> to our     Florida <font color="blue">property amounts</font> to 1prca of any loss and coverage for earthquake     damage to our <font color="blue">California </font>properties is limited to dlra10 million</td>
    </tr>
    <tr>
      <td>Further,     <font color="blue">while insurance reimburses us</font> for our lost gross <font color="blue">earnings during</font> a business     <font color="blue">interruption</font>, if we are unable to supply our customers with our products for     an <font color="blue">extended period</font> of time, there can be no assurance that we will regain     the customers’ business once the <font color="blue">product supply</font> is returned to normal</td>
    </tr>
  </tbody>
</table>